文献速递神经免疫

基于分子标志物的多发性硬化及其进展期诊断

Molecular-based diagnosis of multiple sclerosis and its progressive stage.
PubMed 文献 · Ann Neurol · 2017-01-01

研究利用DNA适配体技术检测1128种脑脊液蛋白,在建模队列(n=225)中开发诊断分类器,并在独立验证队列(n=85)中验证。区分多发性硬化与模拟疾病分类器的验证AUROC为0.98,区分复发缓解型与进展型为0.91,但无法区分原发进展型与继发进展型。治疗引起的标志物变化远超个体内和技术变异。

要点

  • 脑脊液蛋白分类器可高精度区分多发性硬化与临床/影像模拟疾病(AUROC 0.98)。
  • 分类器可区分复发缓解型与进展型多发性硬化(AUROC 0.91)。
  • 原发进展型与继发进展型多发性硬化无法通过分类器区分。

核心结论

  • 脑脊液标志物反映的中枢神经系统生物学过程稳健、稳定、疾病特异甚至疾病阶段特异。

研究设计与样本

  • 建模队列n=225,基于DNA适配体测量1128种脑脊液蛋白,用统计学习开发诊断分类器。
  • 独立验证队列n=85评估分类器可靠性。
  • 体外建模原代或干细胞来源的人中枢神经系统细胞及细胞系用于生物学解释。

主要发现

  • 区分多发性硬化与临床、病理生理及影像学模拟疾病的分类器验证AUROC为0.98。
  • 区分复发缓解型与进展型多发性硬化的分类器验证AUROC为0.91。
  • 区分原发进展型与继发进展型多发性硬化的分类器未优于随机猜测。
  • 治疗引起的标志物变化远大于个体内和技术变异。

临床怎么用

  • 脑脊液蛋白标志物有望用于中枢神经系统疾病的药物开发和精准医疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biomarkers aid diagnosis, allow inexpensive screening of therapies, and guide selection of patient-specific therapeutic regimens in most internal medicine disciplines. In contrast, neurology lacks validated measurements of the physiological status, or dysfunction(s) of cells of the central nervous system (CNS). Accordingly, patients with chronic neurological diseases are often treated with a single disease-modifying therapy without understanding patient-specific drivers of disability. Therefore, using multiple sclerosis (MS) as an example of a complex polygenic neurological disease, we sought to determine whether cerebrospinal fluid (CSF) biomarkers are intraindividually stable, cell type-, disease- and/or process-specific, and responsive to therapeutic intervention. METHODS: We used statistical learning in a modeling cohort (n = 225) to develop diagnostic classifiers from DNA-aptamer-based measurements of 1,128 CSF proteins. An independent validation cohort (n = 85) assessed the reliability of derived classifiers. The biological interpretation resulted from in vitro modeling of primary or stem cell-derived human CNS cells and cell lines. RESULTS: The classifier that differentiates MS from CNS diseases that mimic MS clinically, pathophysiologically, and on imaging achieved a validated area under the receiver operating characteristic curve (AUROC) of 0.98, whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a validated AUROC of 0.91. No classifiers could differentiate primary progressive from secondary progressive MS better than random guessing. Treatment-induced changes in biomarkers greatly exceeded intraindividual and technical variabilities of the assay. INTERPRETATION: CNS biological processes reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific. This opens opportunities for broad utilization of CSF biomarkers in drug development and precision medicine for CNS disorders. Ann Neurol 2017;82:795-812.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Barbour C, Kosa P, Komori M, et al. Molecular-based diagnosis of multiple sclerosis and its progressive stage. Ann Neurol. 2017. PMID: 29059494. doi:10.1002/ana.25083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。